OakChart

Caris Life Sciences Inc

CAIHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

24.49+0.06 (0.25%)
2026-11-12 03:46 CET
Market cap
7,023.36 USD m
Revenue, TTM
1,048.13 USD m
Net income, TTM
96.06 USD m
Free cash flow, TTM
21.20 USD m
EPS diluted, TTM
0.34
P/E
72.52
Compare

Price

CAI against its 20, 50 and 200-day averages
2050200beatmiss
15.0020.0025.0030.0035.007.4M14.7MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CAIclose 24.4920-day 30.8150-day 29.45200-day 21.6524.4952w high52w low

32.9% under the 52-week high of 36.50 on 28 Oct 2026. 52-week low 14.19 on 13 May 2026. Last 15 sessions, 53.0% high to low

Volume 1.00× normal · the line is the 50-bar volume average

Profile

CAI
52-week range, 46% of the way up
14.1936.50

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

IndexRUI
Employees1846
IPOJun 18, 2025
Beta1.05
ATR, 14d2.28
Rel volume1.00
Short float8.97%
Insider own55.29%
Inst own54.43%

Snapshot

6 groups

Valuation

IndexRUI
Market Cap7.02B
Enterprise Value6.72B
Income96.06M
Sales1.05B
Book/sh2.23
Cash/sh2.68
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees1846
IPOJun 18, 2025

Ratios

P/E72.52
Forward P/E87.46
PEG-
P/S6.70
P/B10.98
P/C9.15
P/FCF331.29
EV/EBITDA41.38
EV/Sales6.41
Quick Ratio5.84
Current Ratio6.71
Debt/Eq0.72
LT Debt/Eq0.71
Option/ShortYes / Yes

Earnings

EPS (ttm)0.34
EPS next Y0.28
EPS next Q0.06
EPS this Y127.81%
EPS next Y147.29%
EPS next 5Y-
EPS past 3/5Y-7.57% -
Sales past 3/5Y62.87% -
EPS Y/Y TTM114.01%
Sales Y/Y TTM61.48%
EPS Q/Q-40.02%
Sales Q/Q26.99%
EarningsNov 04 AMC
EPS/Sales Surpr.77.94% 7.83%

Ownership

Insider Own55.29%
Insider Trans-0.57%
Inst Own54.43%
Inst Trans-5.72%
ROA8.58%
ROE17.19%
ROIC8.76%
Gross Margin69.09%
Oper. Margin13.35%
Profit Margin9.16%
SMA20-20.51%
SMA50-16.84%
SMA20013.09%
Trades-

Technical

Shs Outstand286.72M
Shs Float128.21M
Short Float8.97%
Short Ratio2.45
Short Interest11.49M
52W High36.50 -32.90%
52W Low14.19 72.59%
Volatility8.34% 6.95%
ATR (14)2.28
RSI (14)33.88
Beta1.05
Rel Volume1.00
Avg Volume4.70M
Volume4,681,065

Performance

Perf Week-26.28%
Perf Month-17.07%
Perf Quarter10.41%
Perf Half Y66.71%
Perf YTD-9.23%
Perf Year-2.66%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.64
Target Price34.23
Prev Close24.43
Price24.49
Change %0.25%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Sep 09, 2026InitiatedUUBSNeutral$28+14.3%
Jun 02, 2026ResumedWWolfe ResearchPeer Perform
Apr 13, 2026InitiatedJJefferiesBuy$28+14.3%
Apr 10, 2026InitiatedPPiper SandlerNeutral$21-14.3%
Apr 01, 2026InitiatedGGoldmanBuy$27+10.2%
Feb 17, 2026InitiatedRRobert W. BairdOutperform$26+6.2%
Dec 02, 2025InitiatedCCanaccord GenuityHold$28+14.3%
Jul 14, 2025InitiatedWWolfe ResearchOutperform$32+30.7%
Jul 14, 2025InitiatedTTD CowenBuy$32+30.7%
Jul 14, 2025InitiatedJJP MorganOverweight$31+26.6%

Peers

Mkt cap
TickerCompanyMkt cap
TEMTempus AI Inc14.49B
GHGuardant Health Inc20.94B
NEONeogenomics Inc2.18B
NTRANatera Inc46.38B
GRALGRAIL Inc5.65B
VCYTVeracyte Inc2.03B
LHLabcorp Holdings Inc30.23B
ADPTAdaptive Biotechnologies Corp4.85B
DGXQuest Diagnostics Inc28.46B
MYGNMyriad Genetics Inc548.68M

Insider trading

latest 14 of 20
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Denton John RusselSee RemarksSep 22 '26Sale31.827,500238,626174,855Sep 23 05:06 PM
JOHN RUSSEL DENTONOfficerSep 22 '26Proposed Sale31.827,500238,626Sep 22 04:08 PM
Brille Brian JSee RemarksSep 17 '26Option Exercise2.44400,000976,000630,303Sep 17 06:08 PM
Brille Brian JSee RemarksSep 17 '26Sale30.33400,00012,132,080230,303Sep 17 06:08 PM
BRIAN J BRILLEOfficerSep 17 '26Proposed Sale30.33400,00012,132,080Sep 17 04:34 PM
Spetzler David BaxleyPresidentSep 03 '26Option Exercise2.441,000,0002,440,0001,530,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Option Exercise2.44250,000610,0001,302,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 03 '26Sale24.86478,00011,882,9901,052,083Sep 04 04:59 PM
Spetzler David BaxleyPresidentSep 04 '26Sale24.76119,2122,951,1171,182,871Sep 04 04:59 PM
DAVID SPETZLEROfficerSep 04 '26Proposed Sale24.76119,2122,951,117Sep 04 04:43 PM
DAVID SPETZLEROfficerSep 03 '26Proposed Sale24.86478,00011,882,984Sep 03 04:45 PM
GEORGE H POSTE REVOCABLE TRUSTFormer AffiliateAug 24 '26Proposed Sale26.06100,0002,606,320Aug 24 04:29 PM
GEORGE H POSTEDirectorAug 07 '26Proposed Sale21.4230,000642,633Aug 07 05:12 PM
GEORGE H POSTEDirectorAug 03 '26Proposed Sale16.2520,000325,000Aug 03 04:10 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IBBiShares Biotechnology ETFAUM: 11.36B
FXHFirst Trust Health Care AlphaDEX FundAUM: 1.19B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
IWPiShares Russell Mid-Cap Growth ETFAUM: 18.09B
IWRiShares Russell Mid-Cap ETFAUM: 58.68B
IWFiShares Russell 1000 Growth ETFAUM: 116.57B

News

latest 14 of 184

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.0500.0280.050275.36255.3613
2026Q22026-08-050.0000.006-0.002263.71238.1111
2026Q12026-05-070.000-0.024-0.002216.17209.4210
2025Q42026-02-260.2800.0490.290292.89240.394
2025Q32025-11-050.080-0.1750.086216.83174.058
2025Q22025-08-12-7.970-0.218-1.840181.4138.048
2025Q12025-05-28-0.383--0.452120.93--
2026Q4--0.059--290.1613
2027Q1--0.037--272.2710
2027Q2--0.072--308.1510
2027Q3--0.078--322.9410
2027Q4--0.094--342.548
2028Q1--0.065--322.582
2028Q2--0.105--357.182
2028Q3--0.120--374.842
2028Q4--0.155--402.632

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-0.407-1.060-0.338812.03759.58
2026FY-0.113--1,045
2027FY-0.280--1,252
2028FY-0.441--1,467
2029FY-0.637--1,662
2030FY-0.635--1,874

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-091318290.16286301.14
2026Q4S2026-11-061317290.39286301.14
2026Q4S2026-11-051316290.84281.6301.14
2026Q4S2026-11-041310294.81281.6306.78
2026Q4S2026-10-261310294.81281.6306.78
2026Q4S2026-10-211310294.81281.6306.78
2026Q4S2026-10-201320294.81281.6306.78
2026Q4S2026-10-1313101294.81281.6306.78
2026Q4S2026-10-1213101294.81281.6306.78
2026Q4S2026-10-0913101294.76281.6306.78
2026Q4S2026-10-0613101294.61281.6306.78
2026Q4S2026-09-081391293.89281.6306.78
2026Q4S2026-08-071291294.24281.6306.78
2026Q4S2026-08-061281293.11268306.78

Estimate history

EPS, annual-1.646-1.346-1.9040.3377
Period202320242025TTM
EPS, quarterly-0.329-0.22-0.452-1.840.0860.29-0.002-0.0020.052
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual306.128412.26812.0331048.13
Period202320242025TTM
Sales, quarterly101.62129.915120.915181.398216.833292.886216.174263.712275.358
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual281.091281.091282.526286.718
Period202320242025MRQ
Shares, quarterly281.091281.091281.091281.091282.103282.526282.651282.583286.718
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue1,048.13812.03412.26306.13
Cost of Goods Sold Incl. D&A323.99272.87233.48216.82
Gross Profit724.14539.17178.7889.31
Selling, General and Administrative Excl. Other584.21494.06435.90408.86
Research and Development129.36101.58113.92116.88
Other Operating Expense0.000.000.000.00
Operating Income139.9445.11-257.12-319.55
Interest Expense42.6456.8550.0231.61
Unusual Expense27.2072.19-18.48-0.18
Net Income Before Taxes97.57-68.09-281.89-341.42
Income Taxes1.510.000.000.00
Consolidated Net Income96.06-68.09-281.89-341.42
Net Income From Continuing Operations96.06-68.09-281.89-341.42
Net Income96.06-537.96-378.26-462.53
EPS (Recurring)0.39-1.73-1.39-1.65
EPS (Basic, Before Extraordinaries)0.34-1.90-1.35-1.65
EPS (Diluted)0.34-1.90-1.35-1.65
EBITDA162.3967.73-208.21-270.55
Non-Operating Income (Expense)27.4815.846.779.57
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense58.0770.0118.6415.24
Price To Earnings Ratio72.5272.52--
Price To Sales Ratio8.639.39--
Gross Margin69.0966.4043.3729.17
Operating Margin13.355.56-62.37-104.38
Net Margin9.16-66.25-91.75-151.09
Shares Outstanding286.72282.53281.09281.09
Market Capitalization7,023.367,023.367,708.26-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue275.36263.71216.17292.89216.83181.40120.92129.91
Cost of Goods Sold Incl. D&A93.0784.1274.8371.9769.3367.7163.8559.21
Gross Profit182.28179.60141.35220.91147.51113.6957.0670.70
Selling, General and Administrative Excl. Other162.97152.67136.07132.50114.86131.67115.01107.75
Research and Development33.8432.3631.3231.8421.6225.0523.0727.11
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income19.3226.935.2888.4132.64-17.99-57.95-37.05
Interest Expense9.259.2312.8111.3613.5119.2112.7813.26
Unusual Expense0.0025.230.001.972.0835.8032.33-12.42
Net Income Before Taxes16.87-0.61-0.6481.9624.32-71.79-102.58-36.95
Income Taxes1.620.02-0.130.000.000.000.000.00
Consolidated Net Income15.25-0.64-0.5181.9624.32-71.79-102.58-36.95
Net Income From Continuing Operations15.25-0.64-0.5181.9624.32-71.79-102.58-36.95
Net Income15.25-0.64-0.5181.9624.32-517.20-127.04-61.95
EPS (Recurring)0.050.06-0.000.290.09-1.75-0.37-0.25
EPS (Basic, Before Extraordinaries)0.05-0.00-0.000.290.09-1.84-0.45-0.22
EPS (Diluted)0.05-0.00-0.000.290.09-1.84-0.45-0.22
EBITDA25.9233.4310.3592.7037.54-11.59-50.91-27.98
Non-Operating Income (Expense)6.816.926.886.877.271.210.490.94
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense14.6117.5512.5413.3713.6528.2914.694.98
Price To Earnings Ratio72.52-------
Price To Sales Ratio8.635.095.579.3913.1514.07--
Gross Margin66.2068.1065.3975.4368.0362.6747.1954.42
Operating Margin7.0110.212.4430.1915.05-9.92-47.93-28.52
Net Margin5.54-0.24-0.2427.9811.22-285.12-105.07-47.68
Shares Outstanding286.72282.58282.65282.53282.10281.09281.09281.09
Market Capitalization7,023.365,037.385,052.537,612.338,507.037,581.197,606.72-

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments800.0967.64125.19
Short Term Receivables112.1488.2455.30
Inventories63.6239.5749.00
Other Current Assets21.9415.7713.12
Total Current Assets997.80211.23242.61
Net Property, Plant & Equipment103.02102.77147.51
Total Investments and Advances2.242.590.00
Intangible Assets19.3419.3419.34
Other Assets3.267.813.43
Total Assets1,125.66343.73412.90
Short Term Debt Incl. Current Port. of LT Debt6.5366.176.59
Accounts Payable39.2127.7926.68
Other Current Liabilities81.4171.4661.87
Total Current Liabilities127.14165.4295.14
Long Term Debt421.16358.09210.52
Provision for Risks Charges0.000.000.00
Other Liabilities0.0597.41126.91
Total Liabilities548.36620.92432.57
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.002,221.652,125.28
Common Equity577.31-2,498.84-2,144.95
Total Shareholders Equity577.31-277.19-19.67
Accumulated Minority Interest0.000.000.00
Total Equity577.31-277.19-19.67
Total Liabilities & Stockholders Equity1,125.66343.73412.90
Book Value Per Share2.04-8.89-7.63
Tangible Book Value Per Share1.97-8.96-7.70
Full-Time Employees1,846--
Price to Book Ratio10.9816.11-
Return on Assets-9.27-74.51-
Return on Equity-45.37--
Return on Invested Capital-6.82-348.43-178.89
Quick Ratio7.351.042.04
Current Ratio7.851.282.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income96.06-68.09-281.89-341.42
Depreciation22.5022.6148.9149.00
Other Funds (Non Cash)102.37154.0416.8423.44
Funds from Operations220.93108.57-216.13-268.97
Extraordinary Item0.000.000.000.00
Changes in Working Capital-144.75-33.13-29.07-7.13
Cash from Operating Activities76.1875.44-245.20-276.10
Capital Expenditures-54.98-16.26-8.44-22.32
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-100.120.0061.38237.09
Purchase of Investments-101.990.000.00-63.40
Sale Or Maturity of Investments1.870.0061.38300.49
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-155.09-16.2652.93214.77
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock29.26695.361.531.86
Repurchase of Common Pref Stock-31.46-0.110.000.00
Sale of Common Pref Stock60.72695.471.531.86
Proceedsfrom Stock Options27.86677.560.000.00
Issuance or Reduction of Debt, Net-34.23-4.11199.828.27
Change in Long Term Debt-34.23-4.11199.828.27
Issuance of Long Term Debt372.240.00199.98189.01
Reduction of Long Term Debt-406.47-4.11-0.16-180.74
Net Financing Active Other Cash Flow-5.76-18.55-1.060.00
Other Financing Activities Uses-5.76-18.55-1.060.00
Cash from Financing Activities-10.74672.70200.2910.13
Exchange Rate Effect-0.180.13-0.000.06
Net Change in Cash-89.83732.018.02-51.13
Free Cash Flow21.2059.19-253.64-298.42
Price to Free Cash Flow426.42128.79--
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments767.38793.12823.46800.09757.01722.69
Short Term Receivables133.32116.8990.52112.1426.7050.89
Inventories138.37123.7976.2963.6249.3040.61
Other Current Assets28.1924.0323.9121.9421.2319.12
Total Current Assets1,067.271,057.831,014.18997.80854.25833.32
Net Property, Plant & Equipment102.3095.7282.67103.0264.0061.31
Total Investments and Advances1.831.833.492.242.242.24
Intangible Assets19.3419.3419.3419.3419.3419.34
Other Assets64.8954.9042.713.2644.7438.84
Total Assets1,255.621,229.621,162.391,125.66984.57955.06
Short Term Debt Incl. Current Port. of LT Debt6.386.546.016.536.617.39
Accounts Payable63.8485.9969.8039.2129.0028.73
Other Current Liabilities88.7398.9168.0881.4150.4254.07
Total Current Liabilities158.95191.44143.90127.1486.0390.18
Long Term Debt456.64445.86424.95421.16420.12411.59
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.550.590.050.050.050.38
Total Liabilities616.14637.89568.90548.36506.21502.15
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity639.48591.73593.49577.31478.36452.90
Total Shareholders Equity639.48591.73593.49577.31478.36452.90
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity639.48591.73593.49577.31478.36452.90
Total Liabilities & Stockholders Equity1,255.621,229.621,162.391,125.66984.57955.06
Book Value Per Share2.232.092.102.041.701.61
Tangible Book Value Per Share2.162.032.031.971.631.54
Full-Time Employees---1,846--
Price to Book Ratio10.988.498.7515.9118.77-2.86
Return on Assets8.589.624.67-9.27--
Return on Equity17.1920.1328.35-45.37--
Return on Invested Capital1.39-0.06-0.058.212.71-8.30
Quick Ratio5.844.886.527.359.368.79
Current Ratio6.715.537.057.859.939.24

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income15.25-0.64-0.5181.9624.32-71.79
Depreciation6.616.545.074.294.876.41
Other Funds (Non Cash)23.4748.9520.039.9219.1474.11
Funds from Operations45.3354.8524.5996.1748.348.73
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-67.57-26.378.29-59.1014.09-1.44
Cash from Operating Activities-22.2528.4832.8837.0762.427.29
Capital Expenditures-17.47-22.07-10.34-5.09-7.09-1.39
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.00-100.120.000.000.000.00
Purchase of Investments0.00-101.990.000.000.000.00
Sale Or Maturity of Investments0.001.870.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-17.47-122.19-10.34-5.09-7.09-1.39
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.00---
Change in Capital Stock14.38-17.680.9231.641.15661.16
Repurchase of Common Pref Stock-10.01-21.360.00-0.090.000.00
Sale of Common Pref Stock24.393.680.9231.731.15661.16
Proceedsfrom Stock Options0.000.000.0027.860.00649.70
Issuance or Reduction of Debt, Net-0.04-13.96-0.04-20.19-5.6921.80
Change in Long Term Debt-0.04-13.96-0.04-20.19-5.6921.80
Issuance of Long Term Debt0.00392.390.00-20.16-5.6725.82
Reduction of Long Term Debt-0.04-406.35-0.04-0.04-0.02-4.02
Net Financing Active Other Cash Flow-0.11-5.26-0.06-0.33-16.56-1.55
Other Financing Activities Uses-0.11-5.26-0.06-0.33-16.56-1.55
Cash from Financing Activities14.23-36.900.8211.11-21.10681.40
Exchange Rate Effect-0.11-0.03-0.01-0.030.060.09
Net Change in Cash-25.59-130.6523.3543.0634.30687.40
Free Cash Flow-39.726.4022.5331.9855.335.90
Price to Free Cash Flow426.4243.3743.65128.79--

Revenue breakdown

Molecular Profiling Services2024: 349.12M 2025: 766.72M
Pharma Research And Development Services2024: 63.15M 2025: 45.31M
Non-US2024: 10.42M 2025: 10.64M
United States2024: 401.84M 2025: 801.39M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.97%11.5M128.2M4.83M
2026-10-1510.76%13.6M126.3M4.94M
2026-09-3011.00%13.9M126.3M4.82M
2026-09-1510.55%13.3M126.3M4.43M
2026-08-3110.83%13.7M126.3M4.12M
2026-08-1411.78%15.0M127.0M3.64M
2026-07-3112.07%14.8M122.3M3.27M
2026-07-159.59%11.7M122.4M2.91M
2026-06-3011.58%14.2M122.5M2.66M
2026-06-159.50%11.6M122.5M2.66M
2026-05-298.76%10.7M122.5M2.57M
2026-05-159.60%11.8M122.5M2.57M
2026-04-3010.61%12.7M120.0M2.30M
2026-04-159.82%11.8M120.0M2.46M
2026-03-318.54%10.3M120.6M2.61M
2026-03-136.26%7.5M120.6M2.33M
2026-02-275.40%6.5M120.6M2.52M
2026-02-135.05%6.1M120.4M2.38M
2026-01-305.11%5.9M115.3M2.30M
2026-01-155.73%6.6M115.3M1.99M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call15.007.4011.4014.004.55610.000.000.942-0.0590.004
call17.505.608.900.003.5850.000.000.876-0.0980.008
call20.003.306.505.002.80786.001.000.831-0.0860.010
call22.501.154.303.002.20320.000.000.727-0.0780.013
call25.000.002.001.701.4591620.000.503-0.1160.015
call30.000.000.200.101.0113802.000.114-0.0420.007
call35.000.000.050.051.5162790.000.098-0.0570.007
call40.000.002.150.051.5131190.000.025-0.0190.002
call45.000.002.150.102.27622.000.000.072-0.0680.005
put15.000.000.250.004.4290.000.00-0.150-0.2100.009
put17.500.002.150.002.1980.000.00-0.124-0.0960.008
put20.000.002.200.751.5600.000.00-0.169-0.0840.010
put22.500.002.550.700.94711.000.00-0.273-0.0750.013
put25.000.152.001.251.1392390.00-0.497-0.1130.015
put30.004.006.905.502.08675.000.00-0.886-0.0390.007
put35.009.0011.809.102.6881620.00-0.969-0.0140.003
put40.0014.0017.4014.163.6990.000.00-0.975-0.0150.002
put45.0019.0022.400.004.1510.000.00-0.978-0.0150.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-05SCHEDULE 13G/ASEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-234Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-148-KCurrent report2026-09-14SEC
2026-09-044Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-09-04144Filing for proposed sale of securities under Rule 144.SEC
2026-09-03144Filing for proposed sale of securities under Rule 144.SEC
2026-08-24144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-14SEC
2026-08-12SCHEDULE 13G/ASEC
2026-08-07144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13G/ASEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-134Statement of changes in beneficial ownership of securities2026-05-15SEC
2026-06-168-A12BSEC
2026-06-16CERTSEC
2026-06-058-KCurrent report2026-06-04SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090027.20M4
2026-080000
2026-070000
2026-060000
2026-051.49M200
2026-040000
2026-030000
2026-020000
2026-010000
2025-12001.65M1
2025-11110.33K200

Institutional holders

Manager% owned
FMR LLC13.56%
J. H. Whitney Equity Partners VI, LLC3.98%
COATUE MANAGEMENT LLC3.47%
BRAIDWELL LP2.92%
Sixth Street Partners Management Company, L.P.2.59%
PointState Capital LP2.42%
JPMORGAN CHASE & CO2.32%
BlackRock, Inc.1.96%
T. Rowe Price Investment Management, Inc.1.80%
VANGUARD PORTFOLIO MANAGEMENT LLC1.71%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.43%
JPMorgan Mid Cap Growth Fund1.17%
Fidelity Contrafund1.09%
VANGUARD SMALL-CAP INDEX FUND1.03%
T. Rowe Price Mid-Cap Growth Fund, Inc.0.96%
VIP Mid Cap Portfolio0.91%
Select Health Care Portfolio0.67%
VANGUARD SMALL-CAP GROWTH INDEX FUND0.60%
Strategic Advisers Fidelity U.S. Total Stock Fund0.60%
Short Duration Bond Fund0.52%

OakChart. CAI. Cached 15 minutes.